Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(166 produits)
- Bcr-Abl(117 produits)
- EGFR(578 produits)
- FAK(72 produits)
- FLT(86 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(179 produits)
- JAK(244 produits)
- PDGFR(129 produits)
- RAAS(89 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(56 produits)
- VDA(2 produits)
- VEGFR(242 produits)
Affichez 6 plus de sous-catégories
2368 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
PACAP-38 (31-38), human, mouse, rat
CAS :PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine productionFormule :C47H83N17O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1062.27KRAS G12D inhibitor 25
CAS :KRAS G12D inhibitor 25 (Compound 148) acts as an inhibitor for KRAS G12C and HSP90α, displaying IC50 values of <0.1 μM and 0.1-1 μM respectively. Additionally, it suppresses the proliferation of MIA PaCa-2 and NCI-H358 cell lines, with EC50 values of <0.1 μM and 0.1-1 μM correspondingly. This compound also promotes the degradation of ERBB2, exhibiting a DC50 of 0.1-1 μM.Formule :C56H62ClN11O6Couleur et forme :SolidMasse moléculaire :1020.62ALK protein ligand-1
CAS :ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.Formule :C24H29ClN6O3SCouleur et forme :SolidMasse moléculaire :517.043Si5-N14
CAS :Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.Formule :C78H160N6O5Si2Couleur et forme :SolidMasse moléculaire :1318.31BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Couleur et forme :Odour SolidDSPE-PEG2000-GE11
DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.Couleur et forme :Odour SolidPROTAC EGFR degrader 6
CAS :PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.Formule :C49H57FN12O5Couleur et forme :SolidMasse moléculaire :913.05AD57
CAS :AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
Formule :C22H20F3N7ODegré de pureté :99.05%Couleur et forme :SoildMasse moléculaire :455.44EGFR-IN-144
EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.Formule :C20H17Cl2N3O3Couleur et forme :SolidMasse moléculaire :418.273SA-PA
SA-PA, a self-assembled intracellular PROTAC leveraging azide-alkyne click chemistry, selectively degrades VEGFR-2, PDGFR-β, and EphB4 proteins within U87 cellsFormule :C40H32ClF3N10O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :873.19EGFR-IN-151
EGFR-IN-151 (Compound 10) inhibits EGFR and its downstream signaling pathways ERK/STAT3. It effectively suppresses the proliferation of various lung cancer cells, with IC50 values of 11.7, 5.19, 7.32, and 1.53 μM for NCI-H1781, HCC827, NCI-H3255, and NCI-H1975, respectively. Additionally, EGFR-IN-151 hinders colony formation and cell migration in H1975, induces G1 phase cell cycle arrest, and triggers apoptosis in H1975 cells.Couleur et forme :Odour SolidALK-IN-13
CAS :ALK-IN-13 is an ALK inhibitor.
Formule :C29H39ClN7O2PCouleur et forme :SolidMasse moléculaire :584.1Axltide
CAS :Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Formule :C63H107N19O20S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1514.77SA-VA
SA-VA, an intracellular self-assembled PROTAC featuring azide and alkyne groups, selectively degrades VEGFR-2 and EphB4 proteins within U87 cells.Formule :C50H53ClF3N11O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1044.54DD 03-171
CAS :Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formule :C55H62N10O8Couleur et forme :SolidMasse moléculaire :991.163ALK-IN-12
CAS :ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.Formule :C24H30ClN6O2PCouleur et forme :SolidMasse moléculaire :500.97CS-VIP 8 TFA
CS-VIP 8 TFA is a selective allosteric inhibitor of the WDR5 protein (Ki= 0.008 μM). It induces a conformational change in the MLL1 complex, leading to the dissociation of MLL1 from the complex, thereby inhibiting the MLL1 histone methyltransferase activity and modulating HOX gene expression. CS-VIP 8 TFA shows potential for research in hematological disorders such as leukemia.Formule :C45H53F7N12O9Couleur et forme :SolidMasse moléculaire :1038.39467EGFR-IN-162
EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.Formule :C27H31N3O2Couleur et forme :SolidMasse moléculaire :429.24163BTK degrader-1
CAS :BTK degrader-1 (compound 1), a bifunctional degrader of Bruton's tyrosine kinase (BTK), demonstrates the capability to be conjugated with CD79b and exhibits anti-tumor effects [1].Formule :C52H54F2N8O6Couleur et forme :SolidMasse moléculaire :925.03CN009543V
CAS :CN009543V is an enhancer of tyrosine phosphorylation of EGFR via downstream signaling pathways.Formule :C12H12N4O6SCouleur et forme :SolidMasse moléculaire :340.31Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
CAS :Phosphopeptide ligand for the src SH2 domain (IC50 = 1 μM). Blocks src interactions with EGFR and FAK.Formule :C32H46N5O17PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :803.71Src Inhibitor 4
Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.Formule :C33H34N4O3Couleur et forme :SolidMasse moléculaire :534.648PROTAC BCR-ABL1 ligand 1
CAS :GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.Formule :C17H12F3N3O2Couleur et forme :SoildMasse moléculaire :347.29VEGFR/PARP-IN-1
VEGFR/PARP-IN-1 (Compound 14b) is a dual inhibitor of VEGFR and PARP with IC50 values of 191 nM and 60.9 nM, respectively.Formule :C29H27N9ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :517.58EGFR/COX-2-IN-1
EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.Formule :C20H17FN6O2S2Couleur et forme :SolidMasse moléculaire :456.52JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Formule :C30H33FN4O3SCouleur et forme :SolidMasse moléculaire :548.67MS9427
CAS :MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.Formule :C48H58ClFN8O12Couleur et forme :SolidMasse moléculaire :993.47Candidalysin
CAS :Candidalysin is a cytolytic peptide toxin initially isolated from *Candida albicans*, exhibiting both toxic and non-toxic properties. It activates epithelial cell signaling pathways by interacting with the epithelial growth factor receptor (EGFR) on host cells, leading to the activation of matrix metalloproteinases (MMP) and calcium ion influx, which results in inflammatory responses and immune cell recruitment. Additionally, Candidalysin exhibits cytotoxicity by causing membrane damage to host cells.Formule :C153H266N38O38S2Couleur et forme :SolidMasse moléculaire :3310.11Coumermycin A1
CAS :Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria.Formule :C55H59N5O20Couleur et forme :SolidMasse moléculaire :1110.092EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Formule :C17H15N7O5SCouleur et forme :SolidMasse moléculaire :429.41EGFR/BRAFV600E-IN-4
EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.Formule :C22H16N4OSCouleur et forme :SolidMasse moléculaire :384.45FGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Formule :C28H26Cl2N4O3Couleur et forme :SolidMasse moléculaire :537.44MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Formule :C25H29ClN8O2Couleur et forme :SolidMasse moléculaire :509Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Degré de pureté :98%Couleur et forme :Odour SolidAntifibrotic agent 1
Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.Formule :C27H23ClN6O2Couleur et forme :SolidMasse moléculaire :498.1571Scr-IN-1
Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.Formule :C26H16ClF3N2O3Couleur et forme :SolidMasse moléculaire :496.87Amuvatinib hydrochloride
CAS :Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Formule :C23H22ClN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :483.97ML 2-23
ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].Formule :C47H53BrCl2N10O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1052.86SIAIS178
CAS :SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).Formule :C50H62ClN11O6S2Degré de pureté :98.07%Couleur et forme :SolidMasse moléculaire :1012.68Ref: TM-T12907
1mg152,00€5mg356,00€10mg485,00€25mg888,00€50mg1.431,00€100mg2.052,00€200mg2.673,00€1mL*10mM (DMSO)393,00€DD0-2363
DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.Formule :C36H36ClFN6O4Couleur et forme :SolidMasse moléculaire :671.16Mersalyl
CAS :Mersalyl is an organic mercurial diuretic.Formule :C13H16HgNNaO6Couleur et forme :SolidMasse moléculaire :505.854DSPE-PEG1000-GE11
DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.Couleur et forme :Odour SolidTYD-68
TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.Couleur et forme :Odour SolidFGFR-IN-19
Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.Formule :C36H42N12O6Couleur et forme :SolidMasse moléculaire :738.335032-Butenamide
CAS :2-Butenamide, FLT3 inhibitor. Affordable Excellence: Reliable Quality You Can TrustFormule :C4H7NOCouleur et forme :SolidMasse moléculaire :85.12-Keto Crizotinib
CAS :2-Keto Crizotinib is an active lactam metabolite of crizotinib.Formule :C21H20Cl2FN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.32WDR5 ligand 2
CAS :WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.Formule :C29H31F3N4O4Couleur et forme :SolidMasse moléculaire :556.576CPD-1224
CAS :CPD-1224, an oral ALK inhibitor derivative, binds cereblon, targets EML4-ALK fusions, and degrades ALK plus L1196M/G1202R mutants.Formule :C43H47ClN8O7SCouleur et forme :SolidMasse moléculaire :855.4Verucopeptin
CAS :Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.Formule :C43H73N7O13Couleur et forme :SolidMasse moléculaire :896.08TL13-12
CAS :TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).Formule :C45H53ClN10O10SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :961.49DSPE-PEG5000-A7R
DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Couleur et forme :Odour SolidAST5902
CAS :AST5902 is the active metabolite of Alflutinib.Formule :C27H29F3N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :554.57TL13-110
CAS :Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).Formule :C49H62ClN9O9SCouleur et forme :SolidMasse moléculaire :988.59FGFR1 inhibitor-2
CAS :FGFR1 inhibitor-2, potent at 4.55 μM IC50 in MDA-MB-231, targets triple-negative breast cancer.Formule :C25H22F5N3O3Couleur et forme :SolidMasse moléculaire :507.461EGFR-IN-83
EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50Formule :C22H17F3N4ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :410.39IMC-D11
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.Couleur et forme :Odour LiquidAnticancer agent 271
Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.Couleur et forme :Odour SolidRR-src
CAS :Tyrosine kinase substrate peptideFormule :C64H106N22O21Degré de pureté :98%Couleur et forme :Lyophilized PowderMasse moléculaire :1519.66EGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Formule :C26H20ClFN4OSCouleur et forme :SolidMasse moléculaire :490.98PROTAC FGFR1 degrader-1
PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.Formule :C46H54N8O8Couleur et forme :SolidMasse moléculaire :846.97EGFR-IN-78
EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.Formule :C23H32BrN7O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :550.51Hck-IN-2
Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.Formule :C36H35FN6O10Couleur et forme :SolidMasse moléculaire :730.696MLK3-IN-1
MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.Formule :C20H16F6N4O2SCouleur et forme :SolidMasse moléculaire :490.422SNIPER(ABL)-058
CAS :SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL proteinFormule :C62H75N11O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1150.39FLT3-IN-21
FLT3-IN-21 (compound LC-3), a potent FLT3 inhibitor with an IC50 value of 8.4 nM, induces apoptosis and arrests the cell cycle in the G1 phase.Formule :C20H22FN5O2Couleur et forme :SolidMasse moléculaire :383.42AMX-818
AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.Couleur et forme :Odour LiquidBCPyr
CAS :BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formule :C58H65F2N11O8Couleur et forme :SolidMasse moléculaire :1082.224Varlitinib Tosylate
CAS :Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).Formule :C36H35ClN6O8S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :811.34Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine
CAS :Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine: an ISAC with anti-HER2, STING agonist ADU-S100, linker; for cancer research.Formule :C51H65N17O19P2S2·xC6H15NCouleur et forme :SolidMasse moléculaire :1447.44HG-7-85-01
CAS :HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.Formule :C31H31F3N6O2SDegré de pureté :98.08%Couleur et forme :SolidMasse moléculaire :608.68hCA/VEGFR-2-IN-2
Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes hCA IX/XII andFormule :C23H26N6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :498.55MET/PDGFRA-IN-2
MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positiveFormule :C29H29N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :491.59PROTAC FLT3/CDKs degrader-1
PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.
Formule :C40H42N12O5Masse moléculaire :770.34011hCA/VEGFR-2-IN-4
hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/Formule :C22H23FN6O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :502.52E7090
CAS :E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.Formule :C32H37N5O6Couleur et forme :SolidMasse moléculaire :587.67VEGFR-2-IN-66
VEGFR-2-IN-66 (Compound 6) is an orally active VEGFR-2 inhibitor with an IC50 of 0.509 µM and an IC50 value of 7.48 μM for inhibiting MCF-7 cell proliferation. Its anticancer activity is exerted through cell cycle arrest, induction of apoptosis (Apoptosis), and modulation of gene expression, making it suitable for breast cancer research.Couleur et forme :Odour SolidDBt-10
DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].Formule :C68H86ClFN16O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1277.96PROTAC FLT-3 degrader 1
CAS :PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD)(IC50 0.6 nM),with anti-proliferative activity.Formule :C52H61N9O9S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1020.23JAK1/TYK2-IN-1
CAS :JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).Formule :C18H20F3N7OCouleur et forme :SolidMasse moléculaire :407.401TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Couleur et forme :Odour SolidAKN-028
CAS :AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.
Formule :C17H14N6Degré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :302.33SJ1008030 formic
SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with anFormule :C43H45N13O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :919.96HAT-SIL-TG-1&AT
HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.Formule :C60H69N17O11SCouleur et forme :SolidMasse moléculaire :1236.36Lyso-Monosialoganglioside GM3
CAS :Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.Formule :C41H74N2O20Couleur et forme :SolidMasse moléculaire :915.028PROTAC FLT3/CDK9 degrader-1
Potent PROTAC degrader for FLT3/CDK9, induces apoptosis, and shows promise for FLT3-ITD mutated AML research.Formule :C48H62N12O7Couleur et forme :SolidMasse moléculaire :919.08Multi-kinase-IN-5
Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,Formule :C19H15N5O2SCouleur et forme :SolidMasse moléculaire :377.42Ibrutinib-biotin
CAS :Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Formule :C56H80N12O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1097.39PROTAC BCR-ABL Degrader-1
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway andFormule :C43H40N10O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :792.84JH-XI-10-02
CAS :JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formule :C53H69N5O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :920.161Abl Cytosolic Substrate
CAS :Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).Formule :C64H101N15O16Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1336.58Syk-IN-4
Syk-IN-4: potent, selective SYK inhibitor, orally bioavailable, IC50=0.31 nM, targets autoimmunity, cancers.Couleur et forme :SolidEGFR-IN-22
CAS :EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).Formule :C38H47BrFN10O2PCouleur et forme :SolidMasse moléculaire :805.72PROTAC EGFR degrader 5
CAS :PROTAC EGFR degrader 5 effectively breaks down EGFR Del19 in HCC827 cells at 34.8 nM, inducing apoptosis and G1 arrest.Formule :C57H72FN13O5SCouleur et forme :SolidMasse moléculaire :1070.33dALK-3
dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.Formule :C39H45ClN7O5PCouleur et forme :SolidMasse moléculaire :758.245SNIPER(ABL)-050
SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.Formule :C68H84N12O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1213.47BV02
CAS :BV02 blocks 14-3-3 interactions, useful in chronic myeloid leukemia research, targets T315I mutant and wild-type Bcr-Abl cells.Formule :C20H15N3O5Degré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :377.35Ref: TM-T60081
2mg34,00€5mg52,00€10mg80,00€25mg161,00€50mg245,00€100mg363,00€200mg515,00€1mL*10mM (DMSO)58,00€BMS-599626 2HCL(714971-09-2 Free base)
CAS :BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.Formule :C27H29Cl2FN8O3Degré de pureté :99.11%Couleur et forme :Odour SolidMasse moléculaire :603.47FGFR1/VEGFR2-IN-1
FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].
Formule :C26H27N4O6PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :522.49GBD-9
CAS :GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formule :C44H47N9O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :797.9hCA/VEGFR-2-IN-1
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual inhibitor targeting both Carbonic Anhydrase (CA) IX/XII and Vascular Endothelial Growth Factor Receptor 2 (Formule :C21H17FN6O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :452.46
